You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Radius Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Radius
International Patents:64
US Patents:10
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Radius

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Radius BINOSTO alendronate sodium TABLET, EFFERVESCENT;ORAL 202344-001 Mar 12, 2012 RX Yes Yes 9,592,195 ⤷  Try for Free Y ⤷  Try for Free
Radius TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes 7,803,770 ⤷  Try for Free ⤷  Try for Free
Radius TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes 8,748,382 ⤷  Try for Free ⤷  Try for Free
Radius TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes 11,977,067 ⤷  Try for Free Y ⤷  Try for Free
Radius TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Radius TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Radius Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2073789 23/2023 Austria ⤷  Try for Free PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 (MITTEILUNG) 20221213
2073789 301235 Netherlands ⤷  Try for Free PRODUCT NAME: ABALOPARATIDE; REGISTRATION NO/DATE: EU/1/22/1706 20221213
2073789 2023C/523 Belgium ⤷  Try for Free PRODUCT NAME: ABALOPARATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1706 20221213
2073789 2390018-6 Sweden ⤷  Try for Free PRODUCT NAME: ABALOPARATIDE; REG. NO/DATE: EU/1/22/1706 20221213
1175904 2007C/048 Belgium ⤷  Try for Free PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
2073789 122023000031 Germany ⤷  Try for Free PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 20221212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Radius Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Radius – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for companies to thrive and innovate. This article delves into the market position, strengths, and strategic insights of Radius Health, a biopharmaceutical company that has made significant strides in the bone health sector. By examining Radius's journey, we can gain valuable insights into the dynamics of the pharmaceutical market and the strategies that drive success in this highly competitive field.

Radius Health: A Brief Overview

Radius Health, founded in 2003, has established itself as a key player in the bone health market. The company's primary focus has been on developing and commercializing innovative therapies for osteoporosis and other bone-related disorders. Radius's flagship product, TYMLOS® (abaloparatide) injection, has been a game-changer in the treatment of postmenopausal women with osteoporosis at high risk for fracture[3].

Market Position and Financial Performance

TYMLOS: The Cornerstone of Radius's Success

TYMLOS has been the driving force behind Radius's market position. Launched in 2017, this innovative osteoporosis treatment has shown impressive growth:

  • In Q4 2021, TYMLOS net revenue reached $65 million, a 9% increase from Q4 2020[1].
  • For the full year 2021, TYMLOS accounted for $219 million in sales, up from $208 million in 2020[5].

This consistent growth demonstrates the product's strong market acceptance and Radius's effective commercialization strategy.

Overall Financial Performance

While TYMLOS has been a success story, Radius's overall financial performance has been mixed:

  • Total net revenue for Q4 2021 was $65 million, a 4% increase from Q4 2020[1].
  • However, for the full year 2021, Radius reported a net loss of $70.2 million, or $1.49 per share[1].

These figures highlight the challenges faced by biopharmaceutical companies in balancing R&D investments with commercial success.

Strengths and Competitive Advantages

Innovative Product Portfolio

Radius's strength lies in its focused approach to bone health. The company has developed a portfolio of innovative products that address significant unmet needs in the osteoporosis market:

  1. TYMLOS (abaloparatide) injection: Approved for postmenopausal women with osteoporosis at high risk for fracture.
  2. Abaloparatide-TD: A transdermal system under development for osteoporosis treatment.
  3. Elacestrant: An investigational selective estrogen receptor degrader (SERD) for breast cancer treatment.

Expanding Market Reach

Radius has been proactive in expanding its market reach:

  • In December 2022, TYMLOS received FDA approval for treating men with osteoporosis at high risk for fracture[7].
  • The company has entered into licensing agreements to commercialize abaloparatide in China and select Asia Pacific territories[7].

These strategic moves demonstrate Radius's commitment to global expansion and addressing diverse patient populations.

Strong Leadership and Expertise

Radius boasts a highly experienced leadership team with a proven track record in commercializing major pharmaceutical brands[3]. This expertise is crucial in navigating the complex pharmaceutical landscape and driving the company's growth strategy.

Strategic Insights and Future Outlook

Focus on Core Competencies

Radius's strategy of focusing on bone health and related therapeutic areas has allowed the company to build deep expertise and a strong market position. This focused approach is likely to continue driving the company's success in the future.

Embracing Digital Transformation

Like many pharmaceutical companies, Radius is likely to invest in digital technologies to enhance its R&D processes, improve patient engagement, and optimize its commercial operations. This digital transformation will be crucial in maintaining competitiveness in an increasingly technology-driven industry.

Expanding Through Strategic Partnerships

Radius's recent licensing agreement with Pharmanovia for the Asia Pacific region demonstrates the company's strategy of leveraging partnerships to expand its global footprint[7]. We can expect more such collaborations in the future as Radius seeks to maximize the potential of its product portfolio.

Navigating Market Challenges

The pharmaceutical industry faces numerous challenges, including pricing pressures, regulatory hurdles, and intense competition. Radius's CEO, Kelly Martin, acknowledged these challenges in a 2022 statement:

"The recent market dislocation for biotechnology and biopharmaceutical company values has been significant. Our view is that capital markets will remain uncertain – for this sector and in terms of values and funding – for the foreseeable future."[1]

Navigating these challenges while maintaining growth will be a key focus for Radius in the coming years.

Competitive Landscape Analysis

Key Competitors

While Radius has carved out a niche in the osteoporosis market, it faces competition from larger pharmaceutical companies with established bone health portfolios. Some key competitors include:

  1. Amgen (Prolia, Evenity)
  2. Eli Lilly (Forteo)
  3. Novartis (Zoledronic acid)

Competitive Strategies

To maintain its competitive edge, Radius employs several strategies:

  1. Product Differentiation: TYMLOS offers a unique mechanism of action compared to other osteoporosis treatments, providing a point of differentiation in a crowded market.

  2. Market Expansion: By expanding into new geographic markets and patient populations (e.g., men with osteoporosis), Radius is broadening its revenue base.

  3. Pipeline Development: Continued investment in R&D, including the development of new formulations (e.g., abaloparatide-TD), helps Radius stay ahead of the competition.

  4. Strategic Partnerships: Collaborations with other companies allow Radius to leverage external expertise and resources, enhancing its competitive position.

The Impact of Going Private

In June 2022, Radius Health announced that it would be acquired by two investment firms, Gurnet Point Capital and Patient Square Capital, in a deal valued at approximately $890 million[5]. This move to go private could have significant implications for Radius's future strategy and competitive position:

  1. Increased Financial Flexibility: As a private company, Radius may have more freedom to make long-term investments without the pressure of quarterly earnings reports.

  2. Potential for Strategic Realignment: The new ownership could lead to a reassessment of Radius's strategic priorities and potentially new directions for the company.

  3. Enhanced Focus on Core Business: Without the distractions of being a public company, Radius may be able to focus more intensely on its core business and product development.

  4. Possible Synergies: The investment firms may bring additional resources or expertise that could enhance Radius's competitive position.

Lessons for the Pharmaceutical Industry

Radius's journey offers several valuable lessons for other players in the pharmaceutical industry:

  1. Focus Matters: Radius's success with TYMLOS demonstrates the value of focusing on a specific therapeutic area and building deep expertise.

  2. Innovation is Key: The company's investment in innovative products like TYMLOS and elacestrant highlights the importance of continuous innovation in maintaining competitiveness.

  3. Adaptability is Crucial: Radius's ability to navigate market challenges and adapt its strategy (e.g., expanding into new markets and patient populations) is a key success factor in the dynamic pharmaceutical landscape.

  4. Strategic Partnerships Can Drive Growth: Radius's licensing agreements and recent acquisition show how strategic partnerships can provide new growth opportunities and enhance competitiveness.

  5. Balance is Essential: While focusing on commercial success, pharmaceutical companies must also manage R&D investments and financial performance to ensure long-term sustainability.

Key Takeaways

  • Radius Health has established a strong position in the bone health market, driven by the success of its flagship product, TYMLOS.
  • The company's focused approach, innovative product portfolio, and strategic partnerships are key strengths that contribute to its competitive advantage.
  • Radius faces challenges including financial pressures and intense competition but has demonstrated adaptability in its strategies.
  • The recent move to go private could provide Radius with increased flexibility and focus to enhance its competitive position.
  • Radius's journey offers valuable lessons for the pharmaceutical industry on the importance of focus, innovation, adaptability, and strategic partnerships.

FAQs

  1. What is Radius Health's main product? Radius Health's main product is TYMLOS® (abaloparatide) injection, approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

  2. How has Radius Health expanded its market reach? Radius has expanded its market reach by obtaining FDA approval for TYMLOS to treat men with osteoporosis and by entering into licensing agreements to commercialize abaloparatide in China and select Asia Pacific territories.

  3. What are some of Radius Health's key competitive advantages? Some of Radius Health's key competitive advantages include its focused approach to bone health, innovative product portfolio, experienced leadership team, and strategic partnerships.

  4. How might Radius Health's acquisition by private equity firms impact its future? The acquisition could provide Radius with increased financial flexibility, potential strategic realignment, enhanced focus on core business, and possible synergies with the new ownership.

  5. What lessons can other pharmaceutical companies learn from Radius Health's journey? Key lessons include the importance of focus in therapeutic areas, continuous innovation, adaptability to market challenges, the value of strategic partnerships, and the need to balance commercial success with R&D investments and financial performance.

Sources cited: [1] https://www.globenewswire.com/news-release/2022/02/24/2391313/31149/en/Radius-Health-Inc-Fourth-Quarter-Full-Year-2021-Results.html [3] https://radiuspharm.com [5] https://www.fiercepharma.com/pharma/radius-health-bought-out-two-investment-firms-890-million [7] https://radiuspharm.com/radius-pharmaceuticals-announces-licensing-agreement-with-pharmanovia-to-register-and-commercialize-abaloparatide-in-china-and-select-asia-pacific-territories/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.